P2Y purinoceptor 2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13P2Y purinoceptor 2 shows late clinical disease relevance led by cystic fibrosis. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P41231. Start with cystic fibrosis, then reuse UniProt P41231 as the stable protein anchor across project notes and exports.
Start with cystic fibrosis, then reuse UniProt P41231 as the stable protein anchor across project notes and exports.
P2Y purinoceptor 2 shows late clinical disease relevance led by cystic fibrosis. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with cystic fibrosis because it currently carries late clinical support. Linked drugs include DENUFOSOL TETRASODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyP2Y purinoceptor 2
Review this target as P2Y purinoceptor 2, mapped to UniProt P41231. Sequence length is 377 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats P2Y purinoceptor 2 as ChEMBL target CHEMBL4398, mapped to UniProt P41231. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether P2Y purinoceptor 2 is the right protein anchor across sources, using UniProt P41231 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cystic fibrosis is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | P2Y purinoceptor 2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P41231 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | P2Y purinoceptor 2 |
| UniProt Accession | P41231 |
| Component Type | Protein |
| Sequence Length | 377 aa |
P2Y purinoceptor 2
Review this target as P2Y purinoceptor 2, mapped to UniProt P41231. Sequence length is 377 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
P2Y purinoceptor 2 shows late clinical disease relevance led by cystic fibrosis. 4 more disease programs remain visible in the same review block.
Start review with cystic fibrosis because it currently carries late clinical support. Linked drugs include DENUFOSOL TETRASODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL241483 | 8.52 | EC50 | 3.0 | Preclinical |
| CHEMBL427685 | 8.52 | EC50 | 3.0 | Preclinical |
| CHEMBL4066222 | 8.5 | Kd | 3.162 | Preclinical |
| CHEMBL239573 | 8.4 | EC50 | 4.0 | Preclinical |
| CHEMBL399017 | 8.3 | EC50 | 5.0 | Preclinical |
| CHEMBL336296 | 8.25 | EC50 | 5.61 | Clinical |
| CHEMBL238542 | 8.22 | EC50 | 6.0 | Preclinical |
| CHEMBL392989 | 8.15 | EC50 | 7.0 | Preclinical |
| CHEMBL241482 | 8.1 | EC50 | 8.0 | Preclinical |
| CHEMBL373780 | 8.1 | EC50 | 8.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 140 | 261 | 6.0 |
| assay format | 16 | 57 | 7.0 |
| cell membrane format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 30 | 3 | 5.8 |
| cell-based format | 18 | 23 | 6.3 |
| cell membrane format | 6 | 12 | 5.2 |
| assay format | 1 | 1 | — |